TRIB Trinity Biotech PLC ADS

Trinity Biotech to Present at Emerging Growth Conference

Trinity Biotech to Present at Emerging Growth Conference

DUBLIN, Ireland, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), today announces that management will present virtually at the Emerging Growth Conference on March 7, 2024. The Company invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Please see the presentation information below.

Presentation Details

Date:Thursday, March 7, 2024
Time:11:25 – 11:55 AM ET
Registration:



About Trinity Biotech Plc

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website:

Contact:Trinity Biotech plc

Des Fitzgerald

(353)-1-2769800		LifeSci Partners, LLC

Eric Ribner

(1)-646-751-4363

E-mail 



EN
08/02/2024

Underlying

TRIBTrinity Biotech PLC ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Trinity Biotech PLC ADS

 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global...

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement DUBLIN, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 11, 2026 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of $1.00 per share, based on the...

February 13, 2026 1 EN
 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Secures Regulatory Approval for Commencement of Upstre...

Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation Approval Marks Final Regulatory Milestone Required to Enable Launch of Upstream Manufacturing Activities Under New Offshored & Outsourced Production Model Expected to Drive Gross Margin Expansion, Improve Working Capital Efficiency, and Enhance Long‑Term Scalability  Represents a Key Final Component of the Company’s Comprehensive Transformation Plan DUBLIN, Ireland, Feb. 10, 2...

February 10, 2026 1 EN
 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global R...

Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global Recognition: Diabetes Care Premier Hb9210™ HbA1c Analyser Becomes the Only System Awarded Prestigious IFCC Gold Classification for 2026 – Reinforces Trinity Biotech’s growing position as a key player in diabetes care innovation – Senior commercial executives of Trinity Biotech are attending the World Health Expo from February 10-12, 2026 DUBLIN, Ireland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management sol...

February 10, 2026 1 EN
 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Announces Agreements to Strengthen Capital Structure a...

Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives -  Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 -  Equity settlement mechanisms also agreed for milestone payments and contingent acquisition consideration DUBLIN, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has entered into a series of agreements w...

December 23, 2025 1 EN
 PRESS RELEASE
Free
TRIB Trinity Biotech...

Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tes...

Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests  - TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA1positive operations in Q3 2025 and expects to achieve strong additional profitability growth in Q1 and Q2 2026 through continued strong execution on its Comprehensive Transformation Plan DUBLIN, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wea...

December 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch